Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Price 'Not Aware' Of Stock Choices During HIP Act Consideration, He Tells Senators

Executive Summary

HHS Secretary Nominee Rep. Tom Price, R-Ga., told members of a key Senate health panel that he was "not aware" of purchases his broker made of stocks in health-care companies including Zimmer Biomet Holdings Inc., shortly after introducing The HIP Act to delay a CMS orthopedics bundled payment program. The appointee also signaled his intentions 'not to pull the rug out' on millions of Americans' insurance coverage in any Affordable Care Act replacement plan he works on.

Advertisement

Related Content

Price Wins Confirmation As US Health Secretary; Verma On Deck For CMS Hearing
HHS Nominee Price's Stock Picks To Surface At Confirmation Hearings
Industry Backs Price To Head HHS, Believes ACA Repeal Will Result In No Coverage Gaps
Fierce Critic Of Obamacare, Medicare Delivery Reforms Tapped To Run HHS
HHS Appointee Burwell Tells Senate Panel IPAB Will ‘Never Be Activated’

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT104336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel